Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 26, 2023 07:13 ET | Source: Rayzebio, Inc.

Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio

Transaction Brings RayzeBio’s Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs to Bristol Myers Squibb’s Leading Oncology...
November 13, 2023 16:01 ET | Source: Rayzebio, Inc.

RayzeBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today...
November 06, 2023 16:05 ET | Source: Rayzebio, Inc.

RayzeBio to Participate in Upcoming Investor Conferences in November 2023

SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (Nasdaq: RYZB), a biopharmaceutical company developing an innovative radiopharmaceutical pipeline to treat different cancers, today...
November 01, 2023 06:00 ET | Source: Rayzebio, Inc.

RayzeBio Appoints Industry Leader Tim Van Hauwermeiren to Its Board of Directors

SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today...
October 24, 2023 08:00 ET | Source: Rayzebio, Inc.

FDA selects RayzeBio to Participate in the Inaugural CDRP Program to Expedite Commercial Manufacturing Readiness for RYZ101 in GEP-NETs

SAN DIEGO, Oct. 24, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today...
October 18, 2023 07:00 ET | Source: Rayzebio, Inc.

RayzeBio to Present at European Society for Medical Oncology (ESMO) Congress

SAN DIEGO, Oct. 18, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today...